液体活检市场－全球产业规模、份额、趋势、机会和预测，按产品、技术、工作流程、样本、循环生物标记、应用、最终用户、地区和竞争格局细分，2020-2030年预测

2024年全球液体切片市场规模为49.3亿美元，预计2030年将以12.50%的复合年增长率成长至99.9亿美元。全球液体活检市场专注于检测和分析体液（主要是血液）中存在的遗传物质（例如循环肿瘤DNA和循环肿瘤细胞）的诊断测试。这种非侵入性方法有助于早期发现癌症、监测治疗效果和识别基因突变，与传统的组织活检相比具有许多优势。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球液体切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过提供（测试服务、试剂盒、平台、其他耗材）
  • 依技术分类（聚合酶炼式反应（PCR）、次世代定序（NGS）、其他）
  • 依工作流程（样本製备、文库製备、定序、资料分析与管理）
  • 依样本类型（血液、尿液、唾液、其他）
  • 透过循环生物标记（循环肿瘤细胞 (CTC)、游离核酸、外泌体和细胞外囊泡）
  • 依应用领域（肿瘤科、非肿​​瘤科）
  • 按最终用户（临床实验室、学术和研究机构、製药和生物技术公司）划分
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球液体切片市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• LungLife AI, Inc.
• Illumina, Inc.
• QIAGEN NV
• NeoGenomics Laboratories, Inc.
• Myriad Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health Inc.
• Natera, Inc.
• Sysmex Corporation
• Abcodia Ltd.
• Dxcover Limited

第十六章：策略建议

第17章调查会社について・免责事项

The Global Liquid Biopsy Market, valued at USD 4.93 Billion in 2024, is projected to experience a CAGR of 12.50% to reach USD 9.99 Billion by 2030. The global liquid biopsy market focuses on diagnostic tests that detect and analyze genetic material, such as circulating tumor DNA and circulating tumor cells, present in bodily fluids, primarily blood. This non-invasive approach facilitates early cancer detection, treatment monitoring, and identification of genetic mutations, offering advantages over traditional tissue

Key Market Drivers

The global liquid biopsy market's expansion is fundamentally propelled by the escalating worldwide cancer burden. The significant increase in cancer diagnoses necessitates accessible, less invasive diagnostic and monitoring tools. According to the World Health Organization and the International Agency for Research in Cancer, in their February 2024 news release "Global cancer burden growing, amidst mounting need for services", an estimated 20 million new cancer cases occurred worldwide in 2022. This prevalence drives demand for technologies enabling early detection, treatment guidance, and disease monitoring with minimal patient discomfort. Increasing regulatory and clinical validation supports market penetration.

Key Market Challenges

The prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms presents a significant impediment to the growth of the global liquid biopsy market. The lack of consistent protocols for assay development, validation, and reporting contributes to variable test performance and potentially inaccurate outcomes. This directly undermines the confidence of healthcare providers in integrating liquid biopsy into routine clinical practice, slowing its broader adoption.

For example, according to a 2024 International Association for the Study of Lung Cancer Global Survey, 26% of surveyed institutions were unaware of any biomarker testing guidelines, while only 54% utilized the comprehensive CAP-IASLC-AMP guidelines. Such discrepancies in guideline awareness and implementation highlight the fragmented landscape of liquid biopsy utilization. This variability complicates comparative analysis across different platforms and laboratories, making it difficult for clinicians to fully trust and rely on the results for critical treatment decisions. Consequently, the market experiences slower expansion as stakeholders exercise caution due to these unresolved issues in standardization and perceived reliability.

Key Market Trends

Multi-analyte and multi-cancer screening development is significantly driving the global liquid biopsy market by enabling the simultaneous detection of various cancer types from a single blood sample. This trend promotes broader, earlier cancer identification, enhancing preventative care and treatment outcomes. In March 2024, the National Institutes of Health launched its Cancer Screening Research Network to evaluate multi-cancer early detection tests, initiating a Vanguard Study enrolling up to 24,000 participants. This highlights national commitment to validating advanced diagnostics. Further demonstrating progress, Exai Bio presented data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, showing its RNA- and AI-based platform achieved 87% overall stage I sensitivity across eight cancer types at 95% specificity in a 3,300 subject study.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• LungLife AI, Inc.
• Illumina, Inc.
• QIAGEN NV
• NeoGenomics Laboratories, Inc.
• Myriad Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health Inc.
• Natera, Inc.
• Sysmex Corporation
• Abcodia Ltd.
• Dxcover Limited

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market, By Offering:

• Testing Services
• Kits
• Platform
• Other Consumables

Liquid Biopsy Market, By Technology:

• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

Liquid Biopsy Market, By Workflow:

• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis & Management

Liquid Biopsy Market, By Sample:

• Blood
• Urine
• Saliva
• Others

Liquid Biopsy Market, By Circulating Biomarkers:

• Circulating Tumor Cells (CTCs)
• Cell-free Nucleic Acids
• Exosomes & Extracellular Vesicles

Liquid Biopsy Market, By Application:

• Oncological
• Non-oncological

Liquid Biopsy Market, By End User:

• Clinical Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Liquid Biopsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Liquid Biopsy Market.

Available Customizations:

Global Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liquid Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
  • 5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
  • 5.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
  • 5.2.4. By Sample (Blood, Urine, Saliva, Others)
  • 5.2.5. By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles)
  • 5.2.6. By Application (Oncological, Non-oncological)
  • 5.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
  • 5.2.8. By Region
  • 5.2.9. By Company (2024)
• 5.3. Market Map

6. North America Liquid Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offering
  • 6.2.2. By Technology
  • 6.2.3. By Workflow
  • 6.2.4. By Sample
  • 6.2.5. By Circulating Biomarkers
  • 6.2.6. By Application
  • 6.2.7. By End User
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Liquid Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offering
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Workflow
      • 6.3.1.2.4. By Sample
      • 6.3.1.2.5. By Circulating Biomarkers
      • 6.3.1.2.6. By Application
      • 6.3.1.2.7. By End User
  • 6.3.2. Canada Liquid Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offering
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Workflow
      • 6.3.2.2.4. By Sample
      • 6.3.2.2.5. By Circulating Biomarkers
      • 6.3.2.2.6. By Application
      • 6.3.2.2.7. By End User
  • 6.3.3. Mexico Liquid Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offering
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Workflow
      • 6.3.3.2.4. By Sample
      • 6.3.3.2.5. By Circulating Biomarkers
      • 6.3.3.2.6. By Application
      • 6.3.3.2.7. By End User

7. Europe Liquid Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offering
  • 7.2.2. By Technology
  • 7.2.3. By Workflow
  • 7.2.4. By Sample
  • 7.2.5. By Circulating Biomarkers
  • 7.2.6. By Application
  • 7.2.7. By End User
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Liquid Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offering
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Workflow
      • 7.3.1.2.4. By Sample
      • 7.3.1.2.5. By Circulating Biomarkers
      • 7.3.1.2.6. By Application
      • 7.3.1.2.7. By End User
  • 7.3.2. France Liquid Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offering
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Workflow
      • 7.3.2.2.4. By Sample
      • 7.3.2.2.5. By Circulating Biomarkers
      • 7.3.2.2.6. By Application
      • 7.3.2.2.7. By End User
  • 7.3.3. United Kingdom Liquid Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offering
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Workflow
      • 7.3.3.2.4. By Sample
      • 7.3.3.2.5. By Circulating Biomarkers
      • 7.3.3.2.6. By Application
      • 7.3.3.2.7. By End User
  • 7.3.4. Italy Liquid Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offering
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Workflow
      • 7.3.4.2.4. By Sample
      • 7.3.4.2.5. By Circulating Biomarkers
      • 7.3.4.2.6. By Application
      • 7.3.4.2.7. By End User
  • 7.3.5. Spain Liquid Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offering
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Workflow
      • 7.3.5.2.4. By Sample
      • 7.3.5.2.5. By Circulating Biomarkers
      • 7.3.5.2.6. By Application
      • 7.3.5.2.7. By End User

8. Asia Pacific Liquid Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offering
  • 8.2.2. By Technology
  • 8.2.3. By Workflow
  • 8.2.4. By Sample
  • 8.2.5. By Circulating Biomarkers
  • 8.2.6. By Application
  • 8.2.7. By End User
  • 8.2.8. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Liquid Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offering
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Workflow
      • 8.3.1.2.4. By Sample
      • 8.3.1.2.5. By Circulating Biomarkers
      • 8.3.1.2.6. By Application
      • 8.3.1.2.7. By End User
  • 8.3.2. India Liquid Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offering
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Workflow
      • 8.3.2.2.4. By Sample
      • 8.3.2.2.5. By Circulating Biomarkers
      • 8.3.2.2.6. By Application
      • 8.3.2.2.7. By End User
  • 8.3.3. Japan Liquid Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offering
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Workflow
      • 8.3.3.2.4. By Sample
      • 8.3.3.2.5. By Circulating Biomarkers
      • 8.3.3.2.6. By Application
      • 8.3.3.2.7. By End User
  • 8.3.4. South Korea Liquid Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offering
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Workflow
      • 8.3.4.2.4. By Sample
      • 8.3.4.2.5. By Circulating Biomarkers
      • 8.3.4.2.6. By Application
      • 8.3.4.2.7. By End User
  • 8.3.5. Australia Liquid Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offering
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Workflow
      • 8.3.5.2.4. By Sample
      • 8.3.5.2.5. By Circulating Biomarkers
      • 8.3.5.2.6. By Application
      • 8.3.5.2.7. By End User

9. Middle East & Africa Liquid Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offering
  • 9.2.2. By Technology
  • 9.2.3. By Workflow
  • 9.2.4. By Sample
  • 9.2.5. By Circulating Biomarkers
  • 9.2.6. By Application
  • 9.2.7. By End User
  • 9.2.8. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Liquid Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offering
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Workflow
      • 9.3.1.2.4. By Sample
      • 9.3.1.2.5. By Circulating Biomarkers
      • 9.3.1.2.6. By Application
      • 9.3.1.2.7. By End User
  • 9.3.2. UAE Liquid Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offering
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Workflow
      • 9.3.2.2.4. By Sample
      • 9.3.2.2.5. By Circulating Biomarkers
      • 9.3.2.2.6. By Application
      • 9.3.2.2.7. By End User
  • 9.3.3. South Africa Liquid Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offering
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Workflow
      • 9.3.3.2.4. By Sample
      • 9.3.3.2.5. By Circulating Biomarkers
      • 9.3.3.2.6. By Application
      • 9.3.3.2.7. By End User

10. South America Liquid Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offering
  • 10.2.2. By Technology
  • 10.2.3. By Workflow
  • 10.2.4. By Sample
  • 10.2.5. By Circulating Biomarkers
  • 10.2.6. By Application
  • 10.2.7. By End User
  • 10.2.8. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Liquid Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offering
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Workflow
      • 10.3.1.2.4. By Sample
      • 10.3.1.2.5. By Circulating Biomarkers
      • 10.3.1.2.6. By Application
      • 10.3.1.2.7. By End User
  • 10.3.2. Colombia Liquid Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offering
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Workflow
      • 10.3.2.2.4. By Sample
      • 10.3.2.2.5. By Circulating Biomarkers
      • 10.3.2.2.6. By Application
      • 10.3.2.2.7. By End User
  • 10.3.3. Argentina Liquid Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offering
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Workflow
      • 10.3.3.2.4. By Sample
      • 10.3.3.2.5. By Circulating Biomarkers
      • 10.3.3.2.6. By Application
      • 10.3.3.2.7. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Liquid Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific, Inc.
• 15.3. PerkinElmer Inc.
• 15.4. LungLife AI, Inc.
• 15.5. Illumina, Inc.
• 15.6. QIAGEN NV
• 15.7. NeoGenomics Laboratories, Inc.
• 15.8. Myriad Genetics, Inc.
• 15.9. Bio-Rad Laboratories, Inc.
• 15.10. Guardant Health Inc.
• 15.11. Natera, Inc.
• 15.12. Sysmex Corporation
• 15.13. Abcodia Ltd.
• 15.14. Dxcover Limited

16. Strategic Recommendations

17. About Us & Disclaimer